期刊
CIRCULATION-HEART FAILURE
卷 14, 期 2, 页码 -出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCHEARTFAILURE.120.007761
关键词
cardiovascular disease; heart failure; mortality; prevalence; risk
资金
- National Heart, Lung, and Blood Institute of the National Institutes of Health [T32HL069771]
- National Institutes of Health/National Heart, Lung, and Blood Institute [KL2TR001424]
- American Heart Association [19TPA34890060]
- National Institutes of Health's National Center for Advancing Translational Sciences [KL2TR001424]
The article highlights the need for targeted prevention of heart failure, emphasizing the importance of quantifying individual patient risks in devising optimal prevention strategies. It discusses the development of HF risk prediction tools and the role of biomarkers in personalized risk estimation, as well as explores the application of genomics-enhanced approaches for HF prevention.
Targeted prevention of heart failure (HF) remains a critical need given the high prevalence of HF morbidity and mortality. Similar to risk-based prevention of atherosclerotic cardiovascular disease, optimal HF prevention strategies should include quantification of risk in the individual patient. In this review, we discuss incorporation of a quantitative risk-based approach into the existing HF staging landscape and the clinical opportunity that exists to translate available data on risk estimation to help guide personalized decision making. We first summarize the recent development of key HF risk prediction tools that can be applied broadly at a population level to estimate risk of incident HF. Next, we provide an in-depth description of the clinical utility of biomarkers to personalize risk estimation in select patients at the highest risk of developing HF. We also discuss integration of genomics-enhanced approaches (eg, Titin [TTN]) and other risk-enhancing features to reclassify risk with a precision medicine approach to HF prevention. Although sequential testing is very likely to identify low and high-risk individuals with excellent accuracy, whether or not interventions based on these risk models prevent HF in clinical practice requires prompt attention including randomized placebo-controlled trials of candidate therapies in risk-enriched populations. We conclude with a summary of unanswered questions and gaps in evidence that must be addressed to move the field of HF risk assessment forward.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据